By Bhanvi Satija and Marleen Kaesebier LONDON, July 21 - Novartis exceeded second-quarter core operating profit forecasts on ...

July 21 - Novartis' second-quarter core operating profit beat market expectations on Tuesday, helped by strong sales of ...

By Bhanvi Satija and Marleen Kaesebier LONDON, July 21 - Novartis beat second-quarter profit forecasts and kept its 2026 ...

The stock is being punished for Entresto’s 50% sales drop, but the quarter still beat on core operating profit thanks to ...

Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma ...

Novartis saw its sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by ...

Newer cancer medicines helped quarterly earnings reach $5.94 billion, while Novartis maintained its full-year guidance.

After Eli Lilly and Boehringer Ingelheim posted a landmark win for their diabetes drug Jardiance in heart failure patients with preserved ejection fraction earlier this month, the pressure is ...

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a ...

Entresto (sacubitril/valsartan) is a brand-name prescription medication and is approved it to treat certain types of heart failure in adults. Additionally, Entresto ...

Entresto (sacubitril/valsartan) is a brand-name drug prescribed to treat heart failure. Entresto has interactions with some other drugs and certain supplements ...

Entresto, a prescription medication for heart failure, can cause side effects ranging from mild issues like dizziness and cough to more severe problems, such as high potassium levels and kidney ...